Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam, The Netherlands.
Dig Liver Dis. 2011 Jul;43(7):548-52. doi: 10.1016/j.dld.2011.01.017. Epub 2011 Mar 4.
Gastrojejunostomy and stentplacement are the most commonly used treatments for malignant gastric outlet obstruction (GOO). The preference for either treatment largely depends on the expected survival. Our objective was to investigate predictors of survival in patients with malignant GOO and to develop a model that could aid in the decision for either gastrojejunostomy or stentplacement.
Prognostic factors for survival were collected from a literature search and evaluated in our patient population, which included 95 retrospectively and 56 prospectively followed cases. All 151 patients were treated with gastrojejunostomy or stentplacement.
A higher WHO performance score was the only significant prognostic factor for survival in our multivariable analysis (HR 2.2 95%CI 1.7-2.9), whereas treatment for obstructive jaundice, gender, age, metastases, weight loss, level of obstruction and pancreatic cancer were not. A prognostic model that includes the WHO score was able to distinguish patients with a poor survival (WHO score 3-4, median survival: 31 days) from those with a relatively intermediate or good survival (WHO score 2, median survival: 69 and WHO score 0-1, median survival: 139 days, respectively).
Only the WHO score is a significant predictor of survival in patients with malignant GOO. A simple prognostic model is able to guide the palliative treatment decision for either gastrojejunostomy (WHO score 0-1) or stentplacement (WHO 3-4) in patients with malignant GOO.
胃空肠吻合术和支架置入术是治疗恶性胃出口梗阻(GOO)最常用的方法。两种治疗方法的选择主要取决于预期生存时间。我们的目的是研究恶性 GOO 患者生存的预测因素,并建立一种能够辅助胃空肠吻合术或支架置入术选择的模型。
从文献检索中收集生存的预后因素,并在包括 95 例回顾性和 56 例前瞻性随访病例的患者人群中进行评估。所有 151 例患者均接受胃空肠吻合术或支架置入术治疗。
在多变量分析中,仅较高的世界卫生组织(WHO)表现评分是生存的唯一显著预后因素(HR 2.2,95%CI 1.7-2.9),而阻塞性黄疸的治疗、性别、年龄、转移、体重减轻、梗阻水平和胰腺癌则不是。包括 WHO 评分在内的预后模型能够区分生存较差的患者(WHO 评分 3-4,中位生存时间:31 天)和生存相对中等或较好的患者(WHO 评分 2,中位生存时间:69 天和 WHO 评分 0-1,中位生存时间:139 天)。
只有 WHO 评分是恶性 GOO 患者生存的显著预测因素。一种简单的预后模型能够指导恶性 GOO 患者的姑息性治疗决策,即胃空肠吻合术(WHO 评分 0-1)或支架置入术(WHO 评分 3-4)。